Insider trading of David A Pierce, a SVP,Pres Urology,Pelvic Health at BSX Boston Scientific Corporation
Most recently David A Pierce sold 8,763 shares worth $243,085.62 on 11 January 2018.
|Shares||Price per share||Total price||Shares after||Source|
|2018-01-11||BSX||David A Pierce||SVP,Pres Urology,Pelvic Health||Sale||8,763||$27.74||$243,085.62||24,201||SEC insider form 4|
|2018-01-09||BSX||David A Pierce||SVP,Pres Urology,Pelvic Health||Option exercise||5,152||$7.41||$38,176.32||38,116||SEC insider form 4|
|2018-01-01||BSX||David A Pierce||SVP,Pres Urology,Pelvic Health||Option exercise||13,341||$0.00||$0.00||37,542||SEC insider form 4|
|2017-06-09||BSX||David A Pierce||SVP,Pres Urology,Pelvic Health||Option exercise||13,562||$11.38||$154,335.56||37,763||SEC insider form 4|
|2017-06-01||BSX||David A Pierce||SVP,Pres Urology,Pelvic Health||Option exercise||2,972||$0.00||$0.00||28,572||SEC insider form 4|
|2017-04-26||BSX||David A Pierce||SVP,Pres Urology,Pelvic Health||Option exercise||10,250||$7.39||$75,747.50||35,850||SEC insider form 4|
|2017-03-03||BSX||David A Pierce||SVP,Pres Urology,Pelvic Health||Sale||25,012||$25.01||$625,550.12||25,600||SEC insider form 4|
|2017-02-28||BSX||David A Pierce||SVP,Pres Urology,Pelvic Health||Option exercise||4,398||$0.00||$0.00||64,794||SEC insider form 4|
|2017-02-27||BSX||David A Pierce||SVP,Pres Urology,Pelvic Health||Sale||3,417||$24.84||$84,878.28||29,816||SEC insider form 4|
|2017-02-24||BSX||David A Pierce||SVP,Pres Urology,Pelvic Health||Option exercise||3,058||$0.00||$0.00||32,075||SEC insider form 4|
|2017-02-23||BSX||David A Pierce||SVP,Pres Urology,Pelvic Health||Option exercise||2,452||$0.00||$0.00||29,813||SEC insider form 4|
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; other coronary therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral arterial disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, it provides products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
- Boston Scientific Corporation, 300 Boston Scientific Way, Marlborough 01752, United States